Expression of SOX10, ABCB5 and CD271 in melanocytic lesions and correlation with survival data of patients with melanoma

Clinical and Experimental Dermatology

Volumn 41, Issue 7, 2016, Pages 709-716

  Gambichler, T ^a   Petig, A L ^a   Stockfleth, E ^a   Stucker M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER B5; NEUROTROPHIN RECEPTOR P75; TRANSCRIPTION FACTOR SOX10;

AGED; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; DYSPLASTIC NEVUS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEVUS; NONHUMAN; PIGMENTED NEVUS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84988515326     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12928     Document Type: Article

References (27)

1. Shakhova O, Cheng P, Mishra PJ et al. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program inmelanoma. PLoS Genet 2015; 11: e1004877.
2. Redmer T, Welte Y, Behrens D et al. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS ONE 2014; 9: e92596.
3. Graf SA, Busch C, Bosserhoff AK et al. SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity. J Invest Dermatol 2014; 134: 2212–20.
4. Cronin JC, Watkins-Chow DE, Incao A et al. SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis. Cancer Res 2013; 73: 5709–18.
5. Buonaccorsi JN, Prieto VG, Torres-Cabala C et al. Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases. Am J Dermatopathol 2014; 36: 124–30.
6. Beltraminelli H, Shabrawi-Caelen LE, Kerl H, Cerroni L. Melan-A-positive, “pseudomelanocytic nests”: a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin. Am J Dermatopathol 2009; 31: 305–8.
7. Loftus SK. Decreased melanoma proliferation and cell survival: turn down your SOX10. Pigment Cell Melanoma Res 2013; 26: 3–4.
8. Shakhova O, Zingg D, Schaefer SM et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 2012; 14: 882–90.
9. Agnarsdóttir M, Sooman L, Bolander A et al. SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res 2010; 20: 468–78.
10. Harris ML, Baxter LL, Loftus SK, Pavan WJ. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res 2010; 23: 496–513.
11. Bakos RM, Maier T, Besch R et al. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol 2010; 19: e89–94.
12. Mascarenhas JB, Littlejohn EL, Wolsky RJ et al. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 2010; 23: 225–37.
13. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol 2008; 32: 1291–8.
14. Civenni G, Walter A, Kobert N et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011; 71: 3098–109.
15. Wilson BJ, Saab KR, Ma J et al. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res 2014; 74: 4196–207.
16. Chartrain M, Riond J, Stennevin A et al. Melanoma chemotherapy leads to the selection of ABCB5 expressing cells. PLoS ONE 2012; 7: e36762.
17. Setia N, Abbas O, Sousa Y et al. Profiling of ABC transporters ABCB5, ABCF2 and nestin-positive stem cells in nevi, in situ and invasive melanoma. Mod Pathol 2012; 25: 1169–75.
18. Frank NY, Margaryan A, Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65: 4320–33.
19. Zabierowski SE, Herlyn M. Learning the ABCs of melanoma-initiating cells. Cancer Cell 2008; 13: 185–7.
20. Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345–9.
21. Cheli Y, Bonnazi VF, Jacquel A et al. CD271 is an imperfect marker for melanoma initiating cells. Oncotarget 2014; 5: 5272–83.
22. Furuta J, Inozume T, Harada K, Shimada S. CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol 2014; 134: 1369–77.
23. Mohamed A, Gonzalez RS, Lawson D et al. Tumor stem cells (CD271, c-kit, SOX10) in melanomas: prognostic and outcome implications. Appl Immunohistochem Mol Morphol 2014; 22: 142–5.
24. Boiko AD, Razorenova OV, van de Rijn M et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133–7.
25. vBröcker EB, Magiera H, Herlyn M. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin. J Invest Dermatol 1991; 96: 662–5.
26. Elder DE, Rodeck U, Thurin J et al. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 1989; 49: 5091–6.
27. Innominato PF, Libbrecht L, van den Oord JJ. Expression of neurotrophins and their receptors in pigment cell lesions of the skin. J Pathol 2001; 194: 95–100.